UPM Appoints Analytical Development Director

UPM Pharmaceuticals has appointed Dr. Chi-Chang Wung to the position of director of Analytical Development. Dr. Wung will oversee UPM's analytical development group.

Daniel Dixon, vice president of Quality Control for UPM, said, "Dr. Wung brings a tremendous amount of experience and knowledge to this key position at UPM. With his diverse experience in analytical development, pharmaceutical development and quality operations, I am confident that Dr. Wung will bring a wealth of knowledge to this pivotal position and provide solid leadership to the analytical development group."

Dr. Wung brings more than 20 years of experience in analytical development, pharmaceutical development, quality operations and CMC consulting to his role at UPM. Previously, he served in senior analytical development and quality control positions at Alkermes, SIGA Technologies and Asymchem Laboratories.

Jim Gregory, chief executive officer of UPM, said, "With decades of experience in analytical development as well as the management of systems and regulatory practices, Dr. Wung brings significant industry expertise and leadership skills to our analytical development group. We are confident that under his direction, the team will rise to new levels of excellence."

"I am excited to be a part of this departmental growth at UPM," said Dr. Wung. "A strong analytical development group is paramount for a CDMO to be successful. My goals are to lead from a quality by design approach, while mentoring my group to strive for excellence within the analytical organization at UPM."

 --------------------------------------------------------------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of en-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.